Key Takeaways:
- French biotech firm EG 427 secures 5 million EUR in a Series A funding round.
- The company is pioneering a unique approach in gene therapy, known as pinpoint gene therapy.
- With this latest injection of funds, EG 427 has raised a total of 17 million EUR over two funding rounds.
- The name of the lead investor has yet to be disclosed.
French biotech firm, EG 427, which is making significant strides in the world of gene therapy, has raised an impressive 5 million EUR in its Series A fundraising round, dated July 13, 2023. The company is located in Paris, Ile-de-France, in the heart of Europe’s thriving biotech scene.
EG 427 is setting new trends in the biotech industry, specializing in an innovative approach called pinpoint gene therapy. As its name suggests, this therapy targets specific genetic markers, promising a new horizon in treating genetic disorders and advancing therapeutic practices.
With this latest fundraise, the total capital raised by EG 427 now stands at a formidable 17 million EUR over two funding rounds, according to Crunchbase. This will likely catapult the company further into the spotlight, drawing interest from key players within the biotech and healthcare industries.
The identities of the investors participating in this round, including the lead investor, have yet to be released. However, given the magnitude of the funding and EG 427’s promising field of work, it’s likely that influential figures within the biotechnology and therapeutics industries have pledged their support.
The funds raised will likely contribute to the acceleration of research and development activities at EG 427, further bolstering the company’s standing within the genetics and therapeutics fields. With the promising future of gene therapy and the increasing interest in biotechnology, EG 427 is definitely one to watch.
Stay tuned for more updates on this exciting development within the biotechnology world!
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
Read the full article here
